Skip to main content

Stryker Hip-Implant Plaintiffs Prepping Up

Stryker Hip-Implant Plaintiffs Prepping Up

Stryker Hip-Implant Plaintiffs Prepping Up

Introduction

From the Stryker Hip-Implant lawsuit comes the news that 3 plaintiffs had put forth a motion to remand three claims to the Massachusetts state court. All three claims were against Surgi-Care, a Massachusetts distributor of the Stryker hip components, wherein the plaintiffs suffered hip replacement complications following implantation of Stryker's Accolade TMZF Hip Stem and LFIT Anatomic V40 Femoral Head. The manufacturer, however, argued that since Surgi-care had no power to make any changes to the design, labeling, or packaging of the LFIT V40 Femoral Heads, the plaintiffs were barred from pursuing claims against Surgi-Care; hence, it could be removed on a pre-emption basis. The plaintiffs, on the other hand, are confident that the defendant's theory for removal is baseless and does not apply to lawsuits that involve devices cleared via the FDA's 510(k) program, which was the case with LFIT V40 Femoral Heads.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!